ClinicalTrials.gg
Active, not recruitingNCT07855094Updated Oct 2, 2026

Wavelight Plus Sightmap-LASIK vs. Wavefront-Optimized-LASIK

An interventional study of LASIK calculated ablation using Wavefront-Optimized and wavelight plus Sightmap (WLP) Guided LASIK calculated in Myopia and Astigmatism, sponsored by 59th Medical Wing. Active, not recruiting at 1 site in United States. Open to participants aged 21 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by 59th Medical Wing · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jan 2026, registered Sep 2026).
Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
21 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 342 studies in Myopia with a site in United States — 27 open to participants now, 44 under way, 3 of them phase 3. Myopia · United States.

Planned enrollment
207th of 294
49 · median 68
Started
2026
with 17 others
No phase
243 of 342
16 open now
Primary completion
2026-10
later than 11 of 43 live
Registered
340th of 342
by date

Among the 342 studies in Myopia with a site in United States, this one is the 207th largest by planned enrollment of the 294 interventional ones that give a count, is one of 18 that started in 2026, is one of 243 with no phase, reaches primary completion later than 11 of the 43 other live ones, and was the 340th registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

27 of the 342 studies in Myopia with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 21 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Myopia with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if the wavelight plus Sightmap (WLP) method or the wavefront-optimized (WFO) method for calculating LASIK customization treatment gives better vision, better satisfaction, and fewer symptoms afterward. The main questions it aims to answer are:

  1. Does the WLP method provide better vision than WFO method?
  2. Does the WLP method provide better patient satisfaction and less symptoms than WFO method?

Researchers will compare two methods for calculating LASIK customization treatment to determine which one is better.

Participants will:

  1. Receive LASIK in both eyes: one eye will receive WLP-LASIK and the other will receive WFO-LASIK.
  2. Be in the study for about three months and will have six clinic visits: a pre-op qualification exam, the surgery visit, and follow-up visits on 1 day, 1 week, 1 month, and 3 months after surgery.
  3. Have several eye test to assess vision and complete a symptom questionnaire. This questionnaire will take approximately ten (10) minutes to complete in person during.
Read the detailed description

Both WLP method and WFO method for calculating LASIK customization treatment are FDA-approved and are both performed routinely as standard of care surgery in the US Military. However, there is limited literature comparing quality of vision after WLP-LASIK and WFO-LASIK refractive surgery. Our objective is to study the 3-month visual outcomes (high and 5% low contrast visual acuity, refractive error, higher order aberrations, contrast sensitivity) and subject-reported satisfaction with vision and quality of vision (i.e., double vision, glare, starburst, halos, etc.) using the PROWL-SS questionnaire following contralateral WLP-LASIK and WFO-LASIK. This is a prospective randomized contralateral study, including 49 subjects. Once consented to participate in the study, subjects will have a comprehensive ocular examination to determine eligibility to undergo simultaneous WLP-LASIK surgery in one eye and WFO-LASIK on the contralateral eye to correct myopia. Surgical treatment will be randomized so there is a 50% chance to receive WLP-LASIK on the right eye and WFO-LASIK on the contralateral eye. Subjects will receive standard of care topical ophthalmic antibiotic and steroid drops. Visual outcomes and patient self-reported symptoms will be assessed at day 1, week 1, month 1, and month 3.

03

Conditions studied

  • Myopia
  • Astigmatism

Keywords

  • Ray-tracing
  • LASIK
  • wavefront-optimized
  • wavelight plus SightMap
04

Who can participate

Ages eligible
21 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and Females between the ages of 21 and 50
  • Monocular CDVA of 20/20 or better
  • Nearsightedness between -2.00 diopters and -8.00 diopters
  • Have similar levels of nearsightedness in each eye (≤2D of difference between eyes)
  • Total spherical equivalent (SE) of no more than -9.0 D
  • Less than or equal to 3.00 diopters of astigmatism
  • Stable refraction (within ±0.50 D) as determined by MRSE for a minimum of 12 months prior to surgery
  • ≤0.50 D MRSE difference between cycloplegic and subjective manifest refractions
  • Active duty and Beneficiary on Tricare Prime or Tricare Select
  • Residing within 60 miles radius from Lackland AFB
  • Willing and able to attend all scheduled study visits as required per protocol

Exclusion criteria

Exclusion Criteria:

  • Subjects with corneal abnormal findings including signs of keratoconus, keratoconus suspect, abnormal corneal topography, epithelial basement membrane disease, pellucid marginal degeneration, corneal degenerations, recurrent corneal erosion, progressive and unstable myopia, irregular or unstable corneal mires on central keratometry images, and subjects whose corneal thickness would cause anticipated treatment would violate the posterior 250 microns (μm) of corneal stroma from the corneal endothelium.
  • Subjects with any ocular disease such as advanced/uncontrolled glaucoma, strabismus, severe dry eye, active eye infection or inflammation, recent herpes eye infection or problems resulting from past infection, or having a cardiac pacemaker/implanted defibrillator.
  • Subjects with active collagen vascular, connective tissue, or immunodeficiency diseases
  • Pregnant or nursing females (pregnancy test will be performed on females subjects of )
  • Systemic disease likely to affect wound healing, such as diabetes and severe atopy, severe allergies
  • Taking the medication Isotretinoin (Accutane), Amiodarone hydrochloride (Cordaroneor), Sumatriptan succinate (Imitrex), antimetabolites for any medical condition
  • Potential candidate who cannot provide will not be allowed to participate
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
49 participants (estimated)

Study arms

  • Experimental
    wavelight plus SightMap-guided LASIK (WLP-LASIK)

    Eye having LASIK Surgery guided by Wavelight Plus SightMap (WLP)

    Procedure: wavelight plus Sightmap (WLP) Guided LASIK calculated

  • Active comparator
    Wavefront-Optimized LASIK (WFO-LASIK)

    Eye having Wavefront-Optimized LASIK eye surgery

    Procedure: LASIK calculated ablation using Wavefront-Optimized

Interventions

  • ProcedureLASIK calculated ablation using Wavefront-Optimized

    WFO LASIK

  • Procedurewavelight plus Sightmap (WLP) Guided LASIK calculated

    WLP Sightmap

06

What researchers measure

Primary outcomes

  1. Percentage of eyes achieving MRSE within ±0.25D at 3-month Post-Op

    Post-operative manifest refraction spherical equivalent (MRSE) within ±0.25D at POM3; unit = percentage of eyes

    Time frame: 3-months Post-Op

Secondary outcomes

  1. Percentage of eyes with Uncorrected Visual Acuity of 20/16 or better at 3-month Post-Op

    Post-operative uncorrected visual acuity of 20/16 or better measure with ETDRS chart; unit = percentage eyes

    Time frame: 3-month Post-Op

Other outcomes

  1. Change in high contrast visual acuity at 3-month Post-Op

    Change in the mean uncorrected visual acuity (unit = logMAR) measure with ETDRS chart from baseline (pre-op) at 3 months Post-Op

    Time frame: Change from baseline (pre-op) to 3-month Post-Op

  2. Change in refractive error at 3-month Post-Op

    Change in the mean refractive error measure with phoropter (unit = diopters) from baseline (pre-op) at 3 months Post-Op

    Time frame: Change from baseline (pre-op) to 3-month Post-Op

  3. Change in low contrast visual acuity at 3-month Post-Op

    Change in the mean low contrast visual acuity (unit = logMAR) measure with ETDRS 5% chart from baseline (pre-op) at 3 months Post-Op

    Time frame: Change from baseline (pre-op) to 3-month Post-Op

  4. Change in Contrast Sensitivity at 3-month Post-Op

    Change in Contrast Sensitivity (unit = cpm) measure with CSV-1000 tester under dim (mesopic) and bright light (photopic) conditions from baseline (pre-op) at 3 months Post-Op

    Time frame: Change from baseline (pre-op) to 3-month Post-Op

  5. Change in higher order aberrations at 3-month Post-Op

    Change in the mean higher order aberrations (unit = root mean square) measure with Wavelight Plus SightMap from baseline (pre-op) at 3 months Post-Op

    Time frame: Change from baseline (pre-op) to 3-month Post-Op

  6. Change in mean score Patient-Reported Outcomes with LASIK Symptoms and Satisfaction (PROWL-SS) Questionnaire at 3-month Post-Op

    The PROWL-SS is a validated tool to assess self-reported symptoms and satisfaction after refractive surgery. Possible Satisfaction Score ranges from 1 (completely satisfied) to 6 (completely dissatisfied). Lower value indicates higher satisfaction. Possible Symptoms Score ranges from 1 (extremely bothersome) to 5 (not at all bothersome). Lower value indicates worse symptoms.

    Time frame: Change from baseline (pre-op) to 3-month Post-Op

07

Study locations

1 site
  • Joint Warfighter Refractive Surgery Center, JBSA Lackland AFB
    San Antonio, Texas 78236, United States
08

References and documents

Publications

  • Khoramnia R, Naujokaitis T, Block L, Fabian K, Kessler LJ, Labuz G, Auffarth GU. Prospective Intraindividual Comparison of Automated Customized Ray-Tracing-Guided versus Wavefront-Optimized LASIK. Ophthalmology. 2025 Oct;132(10):1169-1179. doi: 10.1016/j.ophtha.2025.05.025. Epub 2025 Jun 5. PubMed 40482723 ↗
  • Cao X, Zhang J, Shao J, Zhang Y, Zheng L. Study of the InnovEyes Sightmap Platform in Comparing Ray-Tracing-Guided LASIK and Topography-Guided LASIK. J Refract Surg. 2024 Dec;40(12):e994-e1002. doi: 10.3928/1081597X-20241030-03. Epub 2024 Dec 1. PubMed 39656251 ↗
  • Kanellopoulos AJ. Ray-Tracing Customization in Myopic and Myopic Astigmatism LASIK Treatments for Low and High Order Aberrations Treatment: 2-Year Visual Function and Psychometric Value Outcomes of a Consecutive Case Series. Clin Ophthalmol. 2024 Feb 22;18:565-574. doi: 10.2147/OPTH.S444174. eCollection 2024. PubMed 38410630 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Oct 2026, 9 months after the start.

Of 202 non-industry interventional studies with no phase under Myopia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 44. This study's planned 9 months is below that.

Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2026
First posted
Oct 2, 2026
StartActual
Jan 6, 2026
Primary completionEst.
Oct 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855094
Lead sponsor
59th Medical Wing
Collaborators
Alcon Research
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Jan 6, 2026
Primary completion
Oct 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Oct 2, 2026

Study contacts

Paramjit K Bhullar, MD
principal investigator · 59th Medical Wing

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion